COVID-19: Mixed Treatment News

First, the good news: A new study of Pfizer’s Paxlovid pill showed it dropped the risk of hospitalization and death by 89%, if taken within 3 days of symptoms onset, The New York Times reports.
The findings, based on a study of 2,246 unvaccinated people, are expected to bolster Pfizer’s case for US FDA authorization of the pill. People in the US could have access to the pill within weeks.
The company also said the antiviral pill is effective against Omicron in lab studies.
And now the worrisome news: The FDA is still considering Merck’s application for its COVID-19 pill molunpiravir and has concerns that the pill, if given to pregnant women, could affect the developing fetus, according to The New York Times.
The Quote: “Do we want to reduce the risk for the mother by 30 percent while exposing the embryo and the fetus to a much higher risk of harm by this drug?” James Hildreth, president of Meharry Medical College in Tennessee, said at a Nov. 30 FDA expert committee meeting. “My answer is no, and there is no circumstance in which I would advise a pregnant woman to take this drug.”

Secondary Topic
Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top